Home Compare DHR vs REGN
Stock Comparison · Structural lead, mixed market

Danaher vs Regeneron Pharmaceuticals: Which Stock Looks Stronger in 2026?

Regeneron Pharmaceuticals holds the cleaner structural position, with the lead spread across profitability and valuation. Danaher does not offset that deficit through any equally strong structural edge elsewhere. On the market side, Regeneron Pharmaceuticals is in better shape — its trend is intact while Danaher's trend has broken down. That puts structure and market broadly in agreement — Regeneron Pharmaceuticals's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in profitability, but valuation adds another real layer to the result. Regeneron Pharmaceuticals, Inc. leads by 21 points on the overall comparison score.

Trajectory Similarity
0.58
Moderately similar
Peer-set rank: #16
within Danaher Corporation's functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

This level of similarity points to a meaningful structural match, though not a tight one.

The strongest overlap appears in recent revenue growth and margin trend.

Similarity drivers
recent revenue growthmargin trend
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
DHR
Danaher Corporation
40
Peer-Score
Signal qualityHigh
vs
REGN
Regeneron Pharmaceuticals, Inc.
61
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: DHR vs REGN Profitability 31 63 Stability 59 65 Valuation 48 80 Growth 20 22 DHR REGN
Gap Ranking
#1 Profitability +32
#2 Valuation +32
#3 Stability +6
#4 Growth +2
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for DHR and REGN Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer DHRREGN Relative valuation Structural strength

Regeneron Pharmaceuticals, Inc. looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Regeneron Pharmaceuticals, Inc. sits in the stronger part of the group on profitability, while Danaher Corporation is closer to mid-pack.
Valuation
Both profiles are strong on valuation, but Regeneron Pharmaceuticals, Inc. leads clearly.
Profitability — Dominant Gap
DHR
31
REGN
63
Gap+32in favour of REGN

Capital efficiency adds support, with a 11.8-point ROIC advantage.

What keeps the gap from being one-sided

Stability is the one area where Danaher Corporation still pushes back materially — it is the steadier name on this dimension, which keeps the result from reading as one-way.

What this means for the comparison

The lead is built on both profitability and valuation, making it broader than a single-dimension result.

Explore full peer positioning in AssetNext

Break down the DHR vs REGN comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-and-valuation comparisons

Explore how DHR and REGN each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.